AI Consensus Investment Thesis
AstraZeneca (AZN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY13,257 GBX
+6.1%+8.3% incl. dividends5-Year
BUY17,943 GBX
+43.5%+59.3% incl. dividendsLatest flagship insight
Biopharma Pipeline Replacement Velocity Collides With Severe Statutory Pricing Pressures
Consensus reflects sharp divergence between headline revenue targets and statutory cash conversion. Robust oncology expansion and rare-disease durability offset imminent Farxiga patent cliffs, but elevated clinical capital intensity and sovereign price negotiations constrain multiple expansion, anchoring an earnings-led rather than valuation-driven trajectory.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Warren Buffett (Value Purist), Superintelligence (Anthropologist), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Elon Musk (Visionary), Machiavelli (Insider), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in AstraZeneca at the forecast anchor (2026-09-18): $15,721 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.1% net dividend yield for AstraZeneca.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in GBX; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (GBX) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 12,651.62 | +1.21% | +1.21% | Oncology volume expansion and rare-disease cash conversion counterbalance initial Farxiga pricing concessions. Defensive institutional rotation supports steady equity accumulation, though elevated research outlays and macro discount rates keep quarterly multiple appreciation measured. |
| Q1 2027 | 12,866.00 | +1.69% | +2.93% | Full-year financial reporting confirms double-digit core earnings progression alongside initial tozorakimab regulatory filings. Strong commercial uptake in breast and lung cancer indications offsets localized emerging-market pricing headwinds, sustaining positive share performance. |
| Q2 2027 | 13,088.77 | +1.73% | +4.71% | Expanding commercial contributions from newly approved therapies accelerate top-line replacement. However, US statutory pricing negotiations and European generic competition on legacy primary-care medicines impose modest gross margin friction, moderating intermediate quarterly gains. |
| Q3 2027 | 13,257.22 | +1.29% | +6.06% | Congress presentations demonstrate sustained clinical efficacy across pivotal oncology pipelines. High-barrier rare-disease therapies generate resilient cash flows, insulating group operating profits from macroeconomic consolidation and supporting steady institutional sponsorship. |
| Q4 2027 | 13,600.93 | +2.59% | +8.81% | Commercial rollouts of respiratory biologics and expanding antibody-drug conjugate indications drive volume growth. Cash generation comfortably absorbs heavy Phase III clinical trial commitments, reassuring allocators of underlying earnings durability into year-end. |
| Q1 2028 | 13,788.57 | +1.38% | +10.31% | Annual financial disclosures validate operating leverage expansion despite peak Farxiga patent-loss headwinds. Solid cash conversion supports dividend progression, though election-year drug pricing rhetoric in major Western markets prevents substantive multiple expansion. |
| Q2 2028 | 14,091.16 | +2.19% | +12.73% | Global label expansions for earlier-line solid tumor regimens broaden addressable patient populations. Incremental gross profit conversion outpaces fixed infrastructure cost growth, driving fundamental earnings upgrades across major international brokerages. |
| Q3 2028 | 14,376.89 | +2.03% | +15.02% | Late-stage cardiometabolic and bispecific pipeline readouts reinforce the medium-term replacement trajectory. Defensive healthcare inflows and easing monetary policy discount rates provide valuation support, maintaining measured quarterly price appreciation. |
| Q4 2028 | 14,695.05 | +2.21% | +17.56% | Manufacturing efficiencies across dedicated biologics facilities lower unit costs, bolstering operating margins. Positive clinical milestone deliveries cushion residual pricing drag, driving disciplined institutional positioning across high-quality pharmaceutical defensives. |
| Q1 2029 | 14,907.31 | +1.44% | +19.26% | Full-year results demonstrate that top-line growth has overcome legacy patent cliffs, with group revenues expanding solidly. Free cash flow generation improves as peak facility capital expenditures begin moderating, supporting equity gains. |
| Q2 2029 | 15,239.96 | +2.23% | +21.92% | Specialty oncology scaling drives operating margins higher, but approaching exclusivity horizons on older targeted biologics temper multiple expansion. The market balances accelerating cash generation against mid-horizon therapeutic life-cycle renewal obligations. |
| Q3 2029 | 15,520.77 | +1.84% | +24.17% | Diversified commercial demand across respiratory, rare-disease, and targeted oncology segments maintains steady volume momentum. Inelastic healthcare spending insulates operating cash generation from wider European economic deceleration, sustaining modest price progress. |
| Q4 2029 | 15,928.91 | +2.63% | +27.43% | Approaching long-range operational milestones, revenue visibility improves substantially. Maturing launch portfolios generate dependable operating cash flows, enabling balance-sheet deleveraging and funding selective pipeline licensing without equity dilution. |
| Q1 2030 | 16,173.75 | +1.54% | +29.39% | Annual reporting confirms total group revenues approaching landmark thresholds, validating long-term corporate execution. While statutory payer discounting caps terminal margins, core earnings per share expansion delivers reliable equity support. |
| Q2 2030 | 16,524.18 | +2.17% | +32.19% | Commercial maturation of next-generation oncology biologics drives operating cash flows to cyclical highs. Stable balance-sheet metrics allow management to broaden shareholder distributions, preserving defensive holding patterns across institutional registers. |
| Q3 2030 | 16,808.76 | +1.72% | +34.47% | Share price consolidation reflects a balanced market weighing substantial multi-year earnings gains against scheduled patent transitions on legacy oncology blockbusters. Non-cyclical patient demand establishes a firm valuation floor. |
| Q4 2030 | 17,118.48 | +1.84% | +36.95% | Closing out the decade, scaled biologic manufacturing and expanded global distribution cement market leadership. High cash conversion supports capital returns, delivering modest end-of-year price appreciation anchored in realized operating profits. |
| Q1 2031 | 17,395.86 | +1.62% | +39.17% | Full-year disclosures confirm structural execution across twenty commercial blockbusters. While top-line growth settles into a mature low-double-digit cadence, strong cash generation preserves fundamental valuation multiples against sovereign debt yields. |
| Q2 2031 | 17,650.36 | +1.46% | +41.20% | Early commercialization of next-generation modalities refreshes pipeline durability beyond mature product cliffs. Steady operating margins and dependable dividend accruals provide resilient equity returns during broader macroeconomic rotation. |
| Q3 2031 | 17,942.89 | +1.66% | +43.54% | The five-year forecast concludes with the enterprise established as a high-barrier biopharmaceutical cash compounder. Normalized earnings yield, robust therapeutic moats, and self-funding innovation justify a firm valuation baseline. |
AstraZeneca functions as an industrial-scale biopharmaceutical replacement engine rather than a passive defensive bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry. The base-case economic argument centers on whether commercial scaling across Daiichi Sankyo-partnered antibody-drug conjugates, respiratory biologics, and rare-disease franchises can outpace mechanical generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry from Farxiga and maturing oncology blockbusters. While top-line revenues track toward high-seventy-billion thresholds by 2030, free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry will lag adjusted operating figures due to persistent capital absorption across clinical trials and onshore manufacturing buildouts. Valuation sensitivity remains tightly tethered to discount rates: in an environment of elevated sovereign yields, an entry multiple above twenty-five times trailing earnings limits multiple-driven rerating. The investment case rests on mid-to-high single-digit revenue expansion translating into low-double-digit core earnings growth.
Key insights
- Partnered oncology assets deliver gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry, but shared licensing economics mean top-line blockbuster growth does not fully convert into distributable equity cash flow.
- High-barrier rare-disease therapies provide vital cash flow inelasticity, effectively subsidizing an annual research and development capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry exceeding twenty-three percent of revenue.
- Sovereign price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry and Medicare negotiations permanently compress late-cycle tail margins, shifting the terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry basis toward volume delivery over pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry.
AstraZeneca is navigating a major shift from older medicines facing patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry to newer, advanced cancer and rare-disease treatments. While sales of older drugs like Farxiga will decline as generic competitors enter the market, growing demand for newer therapies like Enhertu and Ultomiris provides strong replacement revenue. However, heavy spending on clinical trials and factory construction means that cash available for dividends and debt reduction will grow more slowly than headline profit figures suggest.
Key insights
- Advanced cancer and rare-disease therapies carry strong pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and high switching barriers, protecting core sales against standard competition.
- Developing new complex medicines requires spending nearly a quarter of company revenues on research, limiting near-term cash payouts.
- Government drug-pricing rules in the United States and Europe permanently reduce late-stage profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry on older blockbuster treatments.
Deep Dive
Outside market sentiment treats AstraZeneca as a premier European pharmaceutical compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry with visible top-line momentum, broadly endorsing management's aspirational eighty-billion-dollar 2030 revenue roadmap. Prevailing consensus relies on continuous oncology market share gains and rare-disease durability, assuming these high-margin pillars will effortlessly neutralize impending Farxiga patent cliffs, Chinese volume-based procurement cuts, and statutory Medicare price concessions.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Outside market sentiment treats AstraZeneca as a premier European pharmaceutical compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry with visible top-line momentum, broadly endorsing management's aspirational eighty-billion-dollar 2030 revenue roadmap. Prevailing consensus relies on continuous oncology market share gains and rare-disease durability, assuming these high-margin pillars will effortlessly neutralize impending Farxiga patent cliffs, Chinese volume-based procurement cuts, and statutory Medicare price concessions.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates structural friction while overestimating intermediate cash conversion, establishing that shares are fairly priced to modestly underpriced on earnings compounding rather than valuation rescue. Market consensus erroneously conflates gross top-line replacement with net distributable cash flows, overlooking that shared partner economics, capital-intensive manufacturing, and statutory price caps suppress cash margins. The analytical edge lies in recognizing that quality volume growth will drive attractive long-term owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry once generic headwinds trough.
Repricing Catalyst
What could make the market recognize and close that gap? Convergence requires consecutive reporting periods in 2027 demonstrating that core operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion and new launch volumes outpace Farxiga generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry. Pivotal Phase III readouts and regulatory approvals for tozorakimab in respiratory disease and datopotamab deruxtecan in lung cancer represent the primary operational triggers. Visible free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry improvements will force sell-side models to de-risk medium-term cash forecasts.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment assessments diverge between confidence in pipeline replacement velocity and caution regarding multi-year patent cliffs. While operational compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry views anticipate valuation stability, skeptical models warn that multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry will persist until generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry is fully absorbed.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macro regimemacro regimeA persistent combination of growth, inflation, policy, and liquidity conditions affecting asset prices.View full glossary entry of higher-for-longer benchmark yields and persistent cost inflation presents a mixed backdrop. Elevated discount rates compress valuation multiples on long-duration clinical pipelines and raise debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry expenses. However, non-cyclical, price-inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry for vital oncology and rare-disease therapies provides exceptional revenue insulation, positioning the company as a defensive compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry during stagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry periods.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across reports centers on terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples and the net cash conversion of the pipeline. Bullish perspectives argue that high-barrier biologics command durable monopoly pricing powermonopoly pricing powerThe ability to sustain prices above competitive levels because effective competition is limited.View full glossary entry, propelling core operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above 32% and justifying a premium multiple near twenty-four times forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry. Conversely, skeptical analyses emphasize that statutory price negotiations, partnered profit splits, and relentless clinical capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry will cap free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry near 3.5%, holding terminal multiplesterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry down around eighteen times. Resolving this tension requires tracking whether reported free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry accelerates alongside core operating earnings through 2027.
Base-Case Forces
Event Risk ScoreVery Low18/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Antibody conjugate and oncology expansion | Innovation And Product | +24% | +30% | Commercial scaling of Daiichi Sankyo-partnered antibody-drug conjugates, particularly Enhertu and datopotamab deruxtecan, drives robust volume expansion across early-line breast and lung cancers. Superior progression-free survival data secures high-margin treatment lines, replacing maturing revenue and insulating top-line growth from primary-care patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry over the forecast window. |
| Alexion rare disease cash compounding | Competitive Positioning | +15% | +18% | Patient migration from Soliris to long-acting Ultomiris alongside novel complement-inhibitor launches creates immense switching barriers in paroxysmal nocturnal hemoglobinuria. Inelastic therapeutic demand and orphan designations yield durable gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry exceeding 85%, generating recurring operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry that systematically funds late-stage pipeline investments without balance-sheet strain. |
| Respiratory biologic commercial lifecycle renewal | Innovation And Product | +14% | +16% | Phase III validation and regulatory submissions for tozorakimab in chronic obstructive pulmonary disease unlock a substantial addressable volume market across broad patient subgroups. Alongside Breztri and Tezspire, this portfolio renewal replaces expiring small-molecule inhaler revenues and preserves long-term specialty respiratory operating profitability. |
| Commercial infrastructure operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry leverage | Operational Efficiency | +12% | +15% | Leveraging established global sales infrastructure allows specialty oncology and biologic launches to scale without proportional selling and administrative expense growth. Rationalized post-acquisition distribution and automated manufacturing compress unit overhead, supporting core operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry progression toward low-thirties percentages and compounding per-share cash earnings. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Farxiga loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry cliff | Sector And Industry | -15% | -18% | Loss of composition-of-matter patent protection on dapagliflozin across the United States and Europe triggers steep generic competition and rapid volume erosion. Stripping away an eight-billion-dollar high-margin pillar creates an acute earnings drag that requires substantial commercial contribution from newer therapies simply to stabilize segment profits. |
| Sovereign drug price negotiation compression | Regulatory | -11% | -13% | Implementation of mandatory Medicare maximum fair price negotiations under the Inflation Reduction Act alongside European reference pricing directly deflates net realized drug prices. Administrative pricing caps permanently truncate the tail-end cash flow of mature blockbusters, reducing terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples across AstraZeneca's primary geographic markets. |
| China regulatory scrutiny and procurement | Political And Geopolitical | -9.0% | -11% | Heightened legal oversight, executive indictments, and expanded Volume-Based Procurement in China suppress realized hospital margins across a market generating over 12% of revenue. Compulsory price reductions on off-patent portfolios and elevated local compliance costscompliance costsExpenses incurred to understand, implement, monitor, and document compliance with laws, regulations, or standards.View full glossary entry dampen regional return on capitalreturn on capitalA measure of profit generated relative to the capital used by a business, with the exact numerator and denominator depending on the convention applied.View full glossary entry and slow international growth momentum. |
| Elevated clinical trial capital absorption | Capital Allocation | -8.0% | -9.0% | Sustaining over one hundred Phase III trials drives annual research and development spending above fourteen billion dollars, consuming roughly a quarter of sales. Escalating developmental complexity and clinical trial inflation dilute near-term free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry, restricting aggressive share repurchase capacity and dividend expansion. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe ADC interstitial lung toxicity crisis | 24% | -23% | Unexpected clustering of drug-related interstitial lung disease or severe off-target toxicities in pivotal Phase III trials by 2027 could prompt regulatory clinical holds or black-box warnings. Such safety setbacks would immediately curtail prescribing adoption in earlier-line settings, vaporizing billions in projected peak oncology cash flows and triggering significant multiple contraction. |
| China systemic hospital procurement debarment | 20% | -20% | Escalation of Chinese criminal probes into formal corporate sanctions, severe financial penalties, or exclusion from the National Reimbursement Drug List by 2027 would sever major emerging-market revenues. Losing unencumbered hospital market access across China would strand local capital infrastructure, impair consolidated operating profits, and inflict severe structural multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Oral GLP1 cardiometabolic registrational triumph | 30% | +24% | Phase III clinical validation of oral GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry candidate elecoglipron demonstrating weight-loss efficacy and tolerability comparable to injectable peptides by 2028 would crack the massive metabolic market. Bypassing cold-chain manufacturing bottlenecks would generate billions in high-margin peak revenue, expanding cardiometabolic earnings and triggering aggressive multiple rerating across global desks. |
| Frontline pan tumor ADC standard displacement | 32% | +20% | Accelerated registrational approvals establishing datopotamab deruxtecan and next-generation bispecifics as unconstrained first-line standards of care in lung and breast cancer by 2028 would broadly displace conventional chemotherapy. Expanding into frontline populations would multiply peak sales forecasts, driving substantial high-margin alliance royalties and expanding group operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. |
Company Financial Analysis
AstraZeneca Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
AstraZeneca's financial trajectory highlights a strong underlying commercial engine transitioning toward high-margin specialty medicine. Fiscal 2025 revenue rose 11% to USD 58.7 billion, and net income reached USD 10.22 billion, supported by robust oncology and rare-disease demand. Trailing twelve-month revenue expanded past USD 61 billion by mid-2026, demonstrating that double-digit volume growth in key cancer therapies has effectively cushioned early pricing pressures on mature cardiovascular lines. However, the composition of these earnings demands careful interpretation. While management's core operating metrics showcase double-digit expansion, reported statutory earnings reflect substantial charges for intangible asset amortization and legal provisions. Free cash flow generation of USD 8.43 billion remains solid, but cash conversion lags adjusted accounting profit due to ongoing launch investments and working capital movements.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 58.7B | USD 10.2B | USD 8.7B |
| 2024 | USD 52.9B | USD 6.9B | USD 7.3B |
| 2023 | USD 46.6B | USD 6.1B | USD 6.6B |
| 2022 | USD 44.3B | USD 3.3B | USD 7.2B |
| 2021 | USD 37.1B | USD 109.9M | USD 3.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 28.3x | TTM | USD-normalized | GBX / USD |
| 2024 | 29.1x | TTM | USD-normalized | GBX / USD |
| 2023 | 35.2x | TTM | USD-normalized | GBX / USD |
| 2022 | 64.5x | Annual | USD-normalized | GBX / USD |
| 2021 | >100x | Annual | USD-normalized | GBX / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability trends showcase meaningful structural expansion as the product portfolio shifts toward advanced biologic therapies. Gross margins widened to 81.9% in fiscal 2025, driven by an increasing mix of high-value oncology and rare-disease medicines that carry superior pricing power. Operating margins reached 23.4%, held in check primarily by deliberate increases in late-stage clinical development expenditure rather than underlying operational inefficiency. Sustaining margin expansion toward management's targeted mid-thirties percentage range will face intermediate friction. As patent expirations on Farxiga erode high-margin metabolic sales and statutory US price negotiation caps realized pricing, product mix will encounter temporary drag. Long-term margin progression depends on whether commercial launch volumes can generate sufficient operating leverage across existing sales infrastructure to absorb fixed research overhead.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 13.7B | 23.4% | 17.4% |
| 2024 | USD 12.5B | 23.7% | 13.0% |
| 2023 | USD 9.6B | 20.5% | 13.0% |
| 2022 | USD 5B | 11.4% | 7.4% |
| 2021 | USD 2.8B | 7.6% | 0.3% |
Balance sheet and leverage
AI Review
AstraZeneca's balance sheet reflects steady post-acquisition deleveraging, with the debt-to-equity ratio moderating to 0.61 by fiscal 2025 as total equity expanded to USD 48.7 billion. Net debt stood near USD 26.9 billion through mid-2026, matched by strong operating earnings that provide comfortable interest coverage exceeding eight times. This financial profile ensures solid debt service capacity and preserves access to commercial credit lines. Nevertheless, headline leverage metrics conceal significant ongoing commitments. A substantial portion of the company's USD 114 billion in assets consists of acquired intangible assets that generate recurring non-cash amortization charges. Furthermore, multi-year clinical collaboration milestones and planned manufacturing localization outlays limit balance-sheet flexibility, meaning major debt-funded acquisitions or aggressive share buybacks remain unlikely over the near term.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 29.6B | USD 5.7B | USD 23.9B net debt | 0.94x |
| 2024 | USD 30.1B | USD 5.6B | USD 24.6B net debt | 0.93x |
| 2023 | USD 28.4B | USD 5.9B | USD 22.6B net debt | 0.81x |
| 2022 | USD 29.1B | USD 6.2B | USD 23B net debt | 0.86x |
| 2021 | USD 30.7B | USD 6.4B | USD 24.4B net debt | 1.16x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains an aggressive reinvestment posture, committing USD 14.23 billion to research and development in fiscal 2025, which represents over 24% of annual revenue. Physical capital expenditure absorbed an additional 10% of sales, directed toward state-of-the-art biologics production and automated antibody-drug conjugate manufacturing facilities in Singapore and the United States. This heavy capital deployment prioritizes scientific leadership over short-term accounting optics. This spending intensity reflects the realities of modern biopharmaceutical replacement. Rather than underinvesting to flatter near-term margins, the enterprise is constructing proprietary manufacturing networks and advancing more than one hundred Phase III clinical programs. While this elevated burn rate constrains immediate free cash flow yield, it builds formidable technical barriers that protect long-term returns on invested capital from generic duplication.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 5.9B | USD 14.2B |
| 2024 | USD 4.6B | USD 12B |
| 2023 | USD 3.8B | USD 10.5B |
| 2022 | USD 2.6B | USD 9.6B |
| 2021 | USD 2.2B | USD 8.4B |
Quarterly Forecast Scenarios
AstraZeneca Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in GBX; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (GBX) | Base case (GBX) | Bull case (GBX) | S&P 500 benchmark (USD) | FX (GBP/USD) |
|---|---|---|---|---|---|
| 12,125 GBX | 12,643 GBX | 13,125 GBX | $750.26 | 1.3237 | |
| 11,640 GBX | 12,830 GBX | 13,650 GBX | $736.44 | 1.3096 | |
| 11,407 GBX | 13,038 GBX | 14,060 GBX | $743.40 | 1.3087 | |
| 11,521 GBX | 13,184 GBX | 14,481 GBX | $755.15 | 1.3116 | |
| 11,291 GBX | 13,522 GBX | 14,916 GBX | $776.22 | 1.3089 | |
| 11,404 GBX | 13,723 GBX | 15,065 GBX | $787.13 | 1.3071 | |
| 11,632 GBX | 14,012 GBX | 15,666 GBX | $802.83 | 1.3128 | |
| 11,632 GBX | 14,288 GBX | 16,136 GBX | $812.05 | 1.3158 | |
| 11,748 GBX | 14,617 GBX | 16,620 GBX | $839.18 | 1.3139 | |
| 11,983 GBX | 14,855 GBX | 16,952 GBX | $850.50 | 1.3090 | |
| 12,223 GBX | 15,209 GBX | 17,631 GBX | $872.39 | 1.3128 | |
| 12,345 GBX | 15,478 GBX | 17,983 GBX | $885.51 | 1.3138 | |
| 12,592 GBX | 15,890 GBX | 18,523 GBX | $909.56 | 1.3168 | |
| 12,844 GBX | 16,170 GBX | 18,893 GBX | $916.13 | 1.3159 | |
| 12,972 GBX | 16,542 GBX | 19,460 GBX | $936.51 | 1.3216 | |
| 13,232 GBX | 16,816 GBX | 19,849 GBX | $947.34 | 1.3218 | |
| 13,364 GBX | 17,133 GBX | 20,246 GBX | $969.59 | 1.3189 | |
| 13,498 GBX | 17,431 GBX | 20,449 GBX | $979.99 | 1.3198 | |
| 13,510 GBX | 17,689 GBX | 20,858 GBX | $999.60 | 1.3236 | |
| 13,633 GBX | 17,975 GBX | 21,275 GBX | $1,012 | 1.3227 |
Behind the synthesis
How each opinion shapes the consensus
The synthesized evidence reveals a clear common pattern: strong organic growth in targeted oncology and rare diseases is colliding with immediate patent expiries on legacy small molecules, notably Farxiga. Multiple reports share the premise that next-generation biologics, particularly antibody-drug conjugates and respiratory therapies, will eventually restore double-digit earnings growth. However, several analyses uncritically project management's eighty-billion-dollar revenue target without discounting partner profit-sharing, statutory US price concessions, or rising clinical capital intensity. The strongest contrarian analyses demonstrate that free cash flow conversion materially lags core accounting profits due to heavy research reinvestment and manufacturing commitments. Factual scrutiny confirms that while commercial replacement velocity is robust, intermediate multiple compression is inevitable as sovereign payers enforce price caps. Consequently, relative weighting prioritizes reports grounded in primary regulatory filings, audited cash flows, and realistic margin structures over those relying on speculative multiple expansion.
Universal Investor AI
The Polymath
GPT-6 AstraDistinguished by meticulous primary source verification, grounded balance-sheet reconciliation, and granular cash conversion tracking. Accurately decouples headline revenue targets from distributable cash flows while properly accounting for partner economics, US policy agreements, and capital deployment.
Universal Investor AI
The Polymath
Opus 5Exhibits superior evidence quality by incorporating recent Phase III readouts, corporate disclosures, executive insider buying, and specific policy agreements. Accurately identifies the divergence between reported IFRS figures and core metrics, grounding cash flow expectations in empirical operational constraints.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashDelivers forensic scrutiny on the gap between core accounting adjustments and statutory cash generation. Accurately maps the timing friction between Farxiga patent cliffs and late-stage respiratory launches, establishing realistic intermediate multiple compression expectations.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides a balanced evaluation of antibody-drug conjugate scaling against Farxiga patent expiration. Demonstrates causal consistency across oncology replacement dynamics, though relies somewhat heavily on standard consensus operating leverage assumptions without fully addressing US pricing negotiation nuances.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashPresents astute analysis of geopolitical positioning, US onshore manufacturing commitments, and executive share purchases. The contrarian perspective on primary listing arbitrage adds insight, though the trajectory relies on somewhat ambitious regulatory resolution speeds in key international markets.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashApplies a sound macroeconomic regime framework, evaluating stagflationary impacts and balance sheet deleveraging with solid discipline. Appropriately balances commercial pipeline productivity against discount rate pressures, presenting an economically consistent through-cycle compounding trajectory.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashApplies rigorous owner-earnings analysis to evaluate capital allocation and platform defensibility. However, its projections slightly underestimate the initial margin dilution caused by generic Farxiga entry and overstate the velocity of small-molecule revenue replacement over the near-term forecast horizon.
Michael Burry AI
The Vulture
Gemini 3.8 FlashMaintains disciplined focus on return on invested capital and valuation multiple compression in an elevated interest rate environment. Correctly details patent cliff vulnerabilities, though errs toward an overly pessimistic view on total franchise revenue substitution.
Universal Investor AI
The Polymath
Gemini 3.8 FlashEffectively tracks antibody-drug conjugate scaling and rare disease durability, articulating a credible path to core operating margin expansion. Its primary limitation is understating the duration of emerging-market pricing headwinds and commercial launch reinvestment demands.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashFeatures robust integration of primary scientific literature and commercial rollout milestones. While its biological moat assessment is exemplary, the projected valuation multiple expansion outpaces realistic limits imposed by persistent sovereign healthcare cost-containment initiatives.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashOffers a trenchant critique of valuation multiples and clinical risk, correctly highlighting demographic tailwinds against therapeutic replacement challenges. However, the path assumes an excessively steep near-term derating that discounts demonstrable commercial demand across established oncology lines.
Elon Musk AI
The Visionary
Gemini 3.8 FlashProvides a valuable skeptical lens on capital intensity and pharmaceutical research treadmill mechanics. While its friction assessments regarding Chinese scrutiny and Farxiga erosion are sound, the model excessively penalizes long-term free cash flow generation from rare-disease assets.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashArticulates an excellent qualitative assessment of therapeutic pricing power and switching barriers within rare diseases. However, its valuation multiple path remains somewhat elevated, giving insufficient weight to near-term free cash flow absorption from heavy clinical trial commitments.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashConstructs an extensive pipeline inventory but suffers from overly aggressive multiple expansion assumptions and hyperbolic top-line compounding projections. Downweighted due to excessive optimism regarding simultaneous blockbusters and minimal allowance for standard biopharma clinical attrition.
Research Provenance
References & Context
This AstraZeneca consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 58 deduplicated sources retained for this batch.
- 01Approval Letter_220359Orig1s000ltr.pdfaccessdata.fda.gov
- 02Selected Drugs and Negotiated Prices | CMScms.gov
- 03ASTRAZENECA PLC - Form 6-K - FY2026sec.gov
- 04ASTRAZENECA PLC - Form 6-K - FY2026sec.gov
- 05Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patientswhitehouse.gov
- 06AstraZeneca stock gains as Enhertu lung-cancer data offsets SERENA-4 setbackad-hoc-news.de
- 07AstraZeneca stock gains despite pipeline setbacks and YTD underperformancead-hoc-news.de
- 08AstraZeneca stock gains on Goldman Sachs target risead-hoc-news.de
- 09Annual report 2025astrazeneca.com
- 10AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patientsastrazeneca.com
- 11AstraZeneca begins trading on the New York Stock Exchangeastrazeneca.com
- 12AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&Dastrazeneca.com
- 13Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionastrazeneca.com
- 14Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancerastrazeneca.com
- 15H1 and Q2 2026 resultsastrazeneca.com
And 43 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 12 periods
Currencies cited: GBP, GBX, USD (quote GBX; primary reporting USD; converted/valuation USD; normalization GBP).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.